Loading…
Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease
The basal ganglia (BG) are a highly organized network, where different parts are activated for specific functions and circumstances. The BG are involved in movement control, as well as associative learning, planning, working memory, and emotion. We concentrate on the “motor circuit” because it is th...
Saved in:
Published in: | Movement disorders 2008, Vol.23 (S3), p.S548-S559 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4582-32b9ecfc6077f158176abdc5aa9ed069c58d6fcce4afa5cbcf685cd466dbabc83 |
---|---|
cites | cdi_FETCH-LOGICAL-c4582-32b9ecfc6077f158176abdc5aa9ed069c58d6fcce4afa5cbcf685cd466dbabc83 |
container_end_page | S559 |
container_issue | S3 |
container_start_page | S548 |
container_title | Movement disorders |
container_volume | 23 |
creator | Obeso, Jose A. Rodríguez-Oroz, Maria Cruz Benitez-Temino, Beatriz Blesa, Franscisco J. Guridi, Jorge Marin, Concepció Rodriguez, Manuel |
description | The basal ganglia (BG) are a highly organized network, where different parts are activated for specific functions and circumstances. The BG are involved in movement control, as well as associative learning, planning, working memory, and emotion. We concentrate on the “motor circuit” because it is the best understood anatomically and physiologically, and because Parkinson's disease is mainly thought to be a movement disorder. Normal function of the BG requires fine tuning of neuronal excitability within each nucleus to determine the exact degree of movement facilitation or inhibition at any given moment. This is mediated by the complex organization of the striatum, where the excitability of medium spiny neurons is controlled by several pre‐ and postsynaptic mechanisms as well as interneuron activity, and secured by several recurrent or internal BG circuits. The motor circuit of the BG has two entry points, the striatum and the subthalamic nucleus (STN), and an output, the globus pallidus pars interna (GPi), which connects to the cortex via the motor thalamus. Neuronal afferents coding for a given movement or task project to the BG by two different systems: (1) Direct disynaptic projections to the GPi via the striatum and STN. (2) Indirect trisynaptic projections to the GPi via the globus pallidus pars externa (GPe). Corticostriatal afferents primarily act to inhibit medium spiny neurons in the “indirect circuit” and facilitate neurons in the “direct circuit.” The GPe is in a pivotal position to regulate the motor output of the BG. Dopamine finely tunes striatal input as well as neuronal striatal activity, and modulates GPe, GPi, and STN activity. Dopaminergic depletion in Parkinson's disease disrupts the corticostriatal balance leading to increased activity the indirect circuit and reduced activity in the direct circuit. The precise chain of events leading to increased STN activity is not completely understood, but impaired dopaminergic regulation of the GPe, GPi, and STN may be involved. The parkinsonian state is characterized by disruption of the internal balance of the BG leading to hyperactivity in the two main entry points of the network (striatum and STN) and excessive inhibitory output from the GPi. Replacement therapy with standard levodopa creates a further imbalance, producing an abnormal pattern of neuronal discharge and synchronization of neuronal firing that sustain the “off” and “on with dyskinesia” states. The effect of levodopa is robust but |
doi_str_mv | 10.1002/mds.22062 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69564500</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69564500</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4582-32b9ecfc6077f158176abdc5aa9ed069c58d6fcce4afa5cbcf685cd466dbabc83</originalsourceid><addsrcrecordid>eNqFkEtvEzEURq0K1IS0i_6ByisQi0lsz_gRdiglAZE-pLZih3XHY6cu80jtGUH49Uya0K6qrq7uvef7FgehE0rGlBA2qYo4ZowIdoCGlKc0UYzLN2hIlOJJShUfoHcx3hNCKafiEA2okooKyYbo57yrTeubGkrchBXU_i9sV9w43N5ZnEPsP_19VXr4hG_ubIC17VpvsK_WpTePdMSuCfgKwi9fx6b-EHHho4Voj9BbB2W0x_s5QrfzLzezr8nycvFt9nmZmIwrlqQsn1rjjCBSOsoVlQLywnCAqS2ImBquCuGMsRk44CY3TihuikyIIofcqHSE3u9616F56GxsdeWjsWUJtW26qMWUi4wT8irItooyJnrw4w40oYkxWKfXwVcQNpoSvbWue-v60XrPnu5Lu7yyxTO519wDkx3w25d283KTPj-7_l-Z7BI-tvbPU6I3rIVMJdc_LhaaXMyXMrv6rs_Tf-YDnVM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21151426</pqid></control><display><type>article</type><title>Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Obeso, Jose A. ; Rodríguez-Oroz, Maria Cruz ; Benitez-Temino, Beatriz ; Blesa, Franscisco J. ; Guridi, Jorge ; Marin, Concepció ; Rodriguez, Manuel</creator><creatorcontrib>Obeso, Jose A. ; Rodríguez-Oroz, Maria Cruz ; Benitez-Temino, Beatriz ; Blesa, Franscisco J. ; Guridi, Jorge ; Marin, Concepció ; Rodriguez, Manuel</creatorcontrib><description>The basal ganglia (BG) are a highly organized network, where different parts are activated for specific functions and circumstances. The BG are involved in movement control, as well as associative learning, planning, working memory, and emotion. We concentrate on the “motor circuit” because it is the best understood anatomically and physiologically, and because Parkinson's disease is mainly thought to be a movement disorder. Normal function of the BG requires fine tuning of neuronal excitability within each nucleus to determine the exact degree of movement facilitation or inhibition at any given moment. This is mediated by the complex organization of the striatum, where the excitability of medium spiny neurons is controlled by several pre‐ and postsynaptic mechanisms as well as interneuron activity, and secured by several recurrent or internal BG circuits. The motor circuit of the BG has two entry points, the striatum and the subthalamic nucleus (STN), and an output, the globus pallidus pars interna (GPi), which connects to the cortex via the motor thalamus. Neuronal afferents coding for a given movement or task project to the BG by two different systems: (1) Direct disynaptic projections to the GPi via the striatum and STN. (2) Indirect trisynaptic projections to the GPi via the globus pallidus pars externa (GPe). Corticostriatal afferents primarily act to inhibit medium spiny neurons in the “indirect circuit” and facilitate neurons in the “direct circuit.” The GPe is in a pivotal position to regulate the motor output of the BG. Dopamine finely tunes striatal input as well as neuronal striatal activity, and modulates GPe, GPi, and STN activity. Dopaminergic depletion in Parkinson's disease disrupts the corticostriatal balance leading to increased activity the indirect circuit and reduced activity in the direct circuit. The precise chain of events leading to increased STN activity is not completely understood, but impaired dopaminergic regulation of the GPe, GPi, and STN may be involved. The parkinsonian state is characterized by disruption of the internal balance of the BG leading to hyperactivity in the two main entry points of the network (striatum and STN) and excessive inhibitory output from the GPi. Replacement therapy with standard levodopa creates a further imbalance, producing an abnormal pattern of neuronal discharge and synchronization of neuronal firing that sustain the “off” and “on with dyskinesia” states. The effect of levodopa is robust but short‐lasting and converts the parkinsonian BG into a highly unstable system, where pharmacological and compensatory effects act in opposing directions. This creates a scenario that substantially departs from the normal physiological state of the BG. © 2008 Movement Disorder Society</description><identifier>ISSN: 0885-3185</identifier><identifier>EISSN: 1531-8257</identifier><identifier>DOI: 10.1002/mds.22062</identifier><identifier>PMID: 18781672</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Afferent Pathways - pathology ; Afferent Pathways - physiopathology ; Animals ; Antiparkinson Agents - therapeutic use ; basal ganglia ; Basal Ganglia - anatomy & histology ; Basal Ganglia - pathology ; Basal Ganglia - physiopathology ; Cerebral Cortex - pathology ; Cerebral Cortex - physiopathology ; Corpus Striatum - pathology ; Corpus Striatum - physiopathology ; globus pallidus ; Globus Pallidus - pathology ; Globus Pallidus - physiopathology ; Haplorhini ; Humans ; medium spiny neurons ; Models, Animal ; Models, Neurological ; Parkinson Disease - drug therapy ; Parkinson Disease - pathology ; Parkinson Disease - physiopathology ; parkinson's disease ; striatum ; subthalamic nucleus</subject><ispartof>Movement disorders, 2008, Vol.23 (S3), p.S548-S559</ispartof><rights>Copyright © 2008 Movement Disorder Society</rights><rights>(c) 2008 Movement Disorder Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4582-32b9ecfc6077f158176abdc5aa9ed069c58d6fcce4afa5cbcf685cd466dbabc83</citedby><cites>FETCH-LOGICAL-c4582-32b9ecfc6077f158176abdc5aa9ed069c58d6fcce4afa5cbcf685cd466dbabc83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18781672$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Obeso, Jose A.</creatorcontrib><creatorcontrib>Rodríguez-Oroz, Maria Cruz</creatorcontrib><creatorcontrib>Benitez-Temino, Beatriz</creatorcontrib><creatorcontrib>Blesa, Franscisco J.</creatorcontrib><creatorcontrib>Guridi, Jorge</creatorcontrib><creatorcontrib>Marin, Concepció</creatorcontrib><creatorcontrib>Rodriguez, Manuel</creatorcontrib><title>Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease</title><title>Movement disorders</title><addtitle>Mov. Disord</addtitle><description>The basal ganglia (BG) are a highly organized network, where different parts are activated for specific functions and circumstances. The BG are involved in movement control, as well as associative learning, planning, working memory, and emotion. We concentrate on the “motor circuit” because it is the best understood anatomically and physiologically, and because Parkinson's disease is mainly thought to be a movement disorder. Normal function of the BG requires fine tuning of neuronal excitability within each nucleus to determine the exact degree of movement facilitation or inhibition at any given moment. This is mediated by the complex organization of the striatum, where the excitability of medium spiny neurons is controlled by several pre‐ and postsynaptic mechanisms as well as interneuron activity, and secured by several recurrent or internal BG circuits. The motor circuit of the BG has two entry points, the striatum and the subthalamic nucleus (STN), and an output, the globus pallidus pars interna (GPi), which connects to the cortex via the motor thalamus. Neuronal afferents coding for a given movement or task project to the BG by two different systems: (1) Direct disynaptic projections to the GPi via the striatum and STN. (2) Indirect trisynaptic projections to the GPi via the globus pallidus pars externa (GPe). Corticostriatal afferents primarily act to inhibit medium spiny neurons in the “indirect circuit” and facilitate neurons in the “direct circuit.” The GPe is in a pivotal position to regulate the motor output of the BG. Dopamine finely tunes striatal input as well as neuronal striatal activity, and modulates GPe, GPi, and STN activity. Dopaminergic depletion in Parkinson's disease disrupts the corticostriatal balance leading to increased activity the indirect circuit and reduced activity in the direct circuit. The precise chain of events leading to increased STN activity is not completely understood, but impaired dopaminergic regulation of the GPe, GPi, and STN may be involved. The parkinsonian state is characterized by disruption of the internal balance of the BG leading to hyperactivity in the two main entry points of the network (striatum and STN) and excessive inhibitory output from the GPi. Replacement therapy with standard levodopa creates a further imbalance, producing an abnormal pattern of neuronal discharge and synchronization of neuronal firing that sustain the “off” and “on with dyskinesia” states. The effect of levodopa is robust but short‐lasting and converts the parkinsonian BG into a highly unstable system, where pharmacological and compensatory effects act in opposing directions. This creates a scenario that substantially departs from the normal physiological state of the BG. © 2008 Movement Disorder Society</description><subject>Afferent Pathways - pathology</subject><subject>Afferent Pathways - physiopathology</subject><subject>Animals</subject><subject>Antiparkinson Agents - therapeutic use</subject><subject>basal ganglia</subject><subject>Basal Ganglia - anatomy & histology</subject><subject>Basal Ganglia - pathology</subject><subject>Basal Ganglia - physiopathology</subject><subject>Cerebral Cortex - pathology</subject><subject>Cerebral Cortex - physiopathology</subject><subject>Corpus Striatum - pathology</subject><subject>Corpus Striatum - physiopathology</subject><subject>globus pallidus</subject><subject>Globus Pallidus - pathology</subject><subject>Globus Pallidus - physiopathology</subject><subject>Haplorhini</subject><subject>Humans</subject><subject>medium spiny neurons</subject><subject>Models, Animal</subject><subject>Models, Neurological</subject><subject>Parkinson Disease - drug therapy</subject><subject>Parkinson Disease - pathology</subject><subject>Parkinson Disease - physiopathology</subject><subject>parkinson's disease</subject><subject>striatum</subject><subject>subthalamic nucleus</subject><issn>0885-3185</issn><issn>1531-8257</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNqFkEtvEzEURq0K1IS0i_6ByisQi0lsz_gRdiglAZE-pLZih3XHY6cu80jtGUH49Uya0K6qrq7uvef7FgehE0rGlBA2qYo4ZowIdoCGlKc0UYzLN2hIlOJJShUfoHcx3hNCKafiEA2okooKyYbo57yrTeubGkrchBXU_i9sV9w43N5ZnEPsP_19VXr4hG_ubIC17VpvsK_WpTePdMSuCfgKwi9fx6b-EHHho4Voj9BbB2W0x_s5QrfzLzezr8nycvFt9nmZmIwrlqQsn1rjjCBSOsoVlQLywnCAqS2ImBquCuGMsRk44CY3TihuikyIIofcqHSE3u9616F56GxsdeWjsWUJtW26qMWUi4wT8irItooyJnrw4w40oYkxWKfXwVcQNpoSvbWue-v60XrPnu5Lu7yyxTO519wDkx3w25d283KTPj-7_l-Z7BI-tvbPU6I3rIVMJdc_LhaaXMyXMrv6rs_Tf-YDnVM</recordid><startdate>2008</startdate><enddate>2008</enddate><creator>Obeso, Jose A.</creator><creator>Rodríguez-Oroz, Maria Cruz</creator><creator>Benitez-Temino, Beatriz</creator><creator>Blesa, Franscisco J.</creator><creator>Guridi, Jorge</creator><creator>Marin, Concepció</creator><creator>Rodriguez, Manuel</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>2008</creationdate><title>Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease</title><author>Obeso, Jose A. ; Rodríguez-Oroz, Maria Cruz ; Benitez-Temino, Beatriz ; Blesa, Franscisco J. ; Guridi, Jorge ; Marin, Concepció ; Rodriguez, Manuel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4582-32b9ecfc6077f158176abdc5aa9ed069c58d6fcce4afa5cbcf685cd466dbabc83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Afferent Pathways - pathology</topic><topic>Afferent Pathways - physiopathology</topic><topic>Animals</topic><topic>Antiparkinson Agents - therapeutic use</topic><topic>basal ganglia</topic><topic>Basal Ganglia - anatomy & histology</topic><topic>Basal Ganglia - pathology</topic><topic>Basal Ganglia - physiopathology</topic><topic>Cerebral Cortex - pathology</topic><topic>Cerebral Cortex - physiopathology</topic><topic>Corpus Striatum - pathology</topic><topic>Corpus Striatum - physiopathology</topic><topic>globus pallidus</topic><topic>Globus Pallidus - pathology</topic><topic>Globus Pallidus - physiopathology</topic><topic>Haplorhini</topic><topic>Humans</topic><topic>medium spiny neurons</topic><topic>Models, Animal</topic><topic>Models, Neurological</topic><topic>Parkinson Disease - drug therapy</topic><topic>Parkinson Disease - pathology</topic><topic>Parkinson Disease - physiopathology</topic><topic>parkinson's disease</topic><topic>striatum</topic><topic>subthalamic nucleus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Obeso, Jose A.</creatorcontrib><creatorcontrib>Rodríguez-Oroz, Maria Cruz</creatorcontrib><creatorcontrib>Benitez-Temino, Beatriz</creatorcontrib><creatorcontrib>Blesa, Franscisco J.</creatorcontrib><creatorcontrib>Guridi, Jorge</creatorcontrib><creatorcontrib>Marin, Concepció</creatorcontrib><creatorcontrib>Rodriguez, Manuel</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Movement disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Obeso, Jose A.</au><au>Rodríguez-Oroz, Maria Cruz</au><au>Benitez-Temino, Beatriz</au><au>Blesa, Franscisco J.</au><au>Guridi, Jorge</au><au>Marin, Concepció</au><au>Rodriguez, Manuel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease</atitle><jtitle>Movement disorders</jtitle><addtitle>Mov. Disord</addtitle><date>2008</date><risdate>2008</risdate><volume>23</volume><issue>S3</issue><spage>S548</spage><epage>S559</epage><pages>S548-S559</pages><issn>0885-3185</issn><eissn>1531-8257</eissn><abstract>The basal ganglia (BG) are a highly organized network, where different parts are activated for specific functions and circumstances. The BG are involved in movement control, as well as associative learning, planning, working memory, and emotion. We concentrate on the “motor circuit” because it is the best understood anatomically and physiologically, and because Parkinson's disease is mainly thought to be a movement disorder. Normal function of the BG requires fine tuning of neuronal excitability within each nucleus to determine the exact degree of movement facilitation or inhibition at any given moment. This is mediated by the complex organization of the striatum, where the excitability of medium spiny neurons is controlled by several pre‐ and postsynaptic mechanisms as well as interneuron activity, and secured by several recurrent or internal BG circuits. The motor circuit of the BG has two entry points, the striatum and the subthalamic nucleus (STN), and an output, the globus pallidus pars interna (GPi), which connects to the cortex via the motor thalamus. Neuronal afferents coding for a given movement or task project to the BG by two different systems: (1) Direct disynaptic projections to the GPi via the striatum and STN. (2) Indirect trisynaptic projections to the GPi via the globus pallidus pars externa (GPe). Corticostriatal afferents primarily act to inhibit medium spiny neurons in the “indirect circuit” and facilitate neurons in the “direct circuit.” The GPe is in a pivotal position to regulate the motor output of the BG. Dopamine finely tunes striatal input as well as neuronal striatal activity, and modulates GPe, GPi, and STN activity. Dopaminergic depletion in Parkinson's disease disrupts the corticostriatal balance leading to increased activity the indirect circuit and reduced activity in the direct circuit. The precise chain of events leading to increased STN activity is not completely understood, but impaired dopaminergic regulation of the GPe, GPi, and STN may be involved. The parkinsonian state is characterized by disruption of the internal balance of the BG leading to hyperactivity in the two main entry points of the network (striatum and STN) and excessive inhibitory output from the GPi. Replacement therapy with standard levodopa creates a further imbalance, producing an abnormal pattern of neuronal discharge and synchronization of neuronal firing that sustain the “off” and “on with dyskinesia” states. The effect of levodopa is robust but short‐lasting and converts the parkinsonian BG into a highly unstable system, where pharmacological and compensatory effects act in opposing directions. This creates a scenario that substantially departs from the normal physiological state of the BG. © 2008 Movement Disorder Society</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>18781672</pmid><doi>10.1002/mds.22062</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0885-3185 |
ispartof | Movement disorders, 2008, Vol.23 (S3), p.S548-S559 |
issn | 0885-3185 1531-8257 |
language | eng |
recordid | cdi_proquest_miscellaneous_69564500 |
source | Wiley-Blackwell Read & Publish Collection |
subjects | Afferent Pathways - pathology Afferent Pathways - physiopathology Animals Antiparkinson Agents - therapeutic use basal ganglia Basal Ganglia - anatomy & histology Basal Ganglia - pathology Basal Ganglia - physiopathology Cerebral Cortex - pathology Cerebral Cortex - physiopathology Corpus Striatum - pathology Corpus Striatum - physiopathology globus pallidus Globus Pallidus - pathology Globus Pallidus - physiopathology Haplorhini Humans medium spiny neurons Models, Animal Models, Neurological Parkinson Disease - drug therapy Parkinson Disease - pathology Parkinson Disease - physiopathology parkinson's disease striatum subthalamic nucleus |
title | Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T21%3A36%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Functional%20organization%20of%20the%20basal%20ganglia:%20Therapeutic%20implications%20for%20Parkinson's%20disease&rft.jtitle=Movement%20disorders&rft.au=Obeso,%20Jose%20A.&rft.date=2008&rft.volume=23&rft.issue=S3&rft.spage=S548&rft.epage=S559&rft.pages=S548-S559&rft.issn=0885-3185&rft.eissn=1531-8257&rft_id=info:doi/10.1002/mds.22062&rft_dat=%3Cproquest_cross%3E69564500%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4582-32b9ecfc6077f158176abdc5aa9ed069c58d6fcce4afa5cbcf685cd466dbabc83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=21151426&rft_id=info:pmid/18781672&rfr_iscdi=true |